Diabetic Gastroparesis-Pipeline Review, H1 2015

Diabetic Gastroparesis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6307IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Gastroparesis-Pipeline Review, H1 2015


Global Markets Direct's, 'Diabetic Gastroparesis-Pipeline Review, H1 2015', provides an overview of the Diabetic Gastroparesis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Gastroparesis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Diabetic Gastroparesis Overview 7

Therapeutics Development 8

Pipeline Products for Diabetic Gastroparesis-Overview 8

Pipeline Products for Diabetic Gastroparesis-Comparative Analysis 9

Diabetic Gastroparesis-Therapeutics under Development by Companies 10

Diabetic Gastroparesis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Diabetic Gastroparesis-Products under Development by Companies 14

Diabetic Gastroparesis-Companies Involved in Therapeutics Development 15

Cempra, Inc. 15

Evoke Pharma, Inc. 16

GlaxoSmithKline plc 17

Ironwood Pharmaceuticals, Inc. 18

Rhythm Pharmaceuticals 19

Shire Plc 20

Targacept, Inc. 21

Diabetic Gastroparesis-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

camicinal-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ETX-101-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ETX-301-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

IW-9179-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

metoclopramide hydrochloride-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

prucalopride succinate-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

relamorelin-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

TC-6499-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

velusetrag-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Diabetic Gastroparesis-Recent Pipeline Updates 46

Diabetic Gastroparesis-Dormant Projects 53

Diabetic Gastroparesis-Discontinued Products 54

Diabetic Gastroparesis-Product Development Milestones 55

Featured News & Press Releases 55

Feb 02, 2015: Evoke Pharma Outlines Progress on Clinical Program 55

Dec 09, 2014: Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis 55

Dec 02, 2014: Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study 56

Sep 09, 2014: Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001 57

Aug 12, 2014: Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 57

Jun 25, 2014: Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis 57

May 28, 2014: Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank 58

May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis 59

Jan 22, 2014: Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 60

Oct 15, 2013: Targacept Scientists to Present Data On TC-6499 at Society for Neuroscience Satellite Meeting 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

Number of Products under Development for Diabetic Gastroparesis, H1 2015 8

Number of Products under Development for Diabetic Gastroparesis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Diabetic Gastroparesis-Pipeline by Cempra, Inc., H1 2015 15

Diabetic Gastroparesis-Pipeline by Evoke Pharma, Inc., H1 2015 16

Diabetic Gastroparesis-Pipeline by GlaxoSmithKline plc, H1 2015 17

Diabetic Gastroparesis-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 18

Diabetic Gastroparesis-Pipeline by Rhythm Pharmaceuticals, H1 2015 19

Diabetic Gastroparesis-Pipeline by Shire Plc, H1 2015 20

Diabetic Gastroparesis-Pipeline by Targacept, Inc., H1 2015 21

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 30

Diabetic Gastroparesis Therapeutics-Recent Pipeline Updates, H1 2015 46

Diabetic Gastroparesis-Dormant Projects, H1 2015 53

Diabetic Gastroparesis-Discontinued Products, H1 2015 54

List of Figures

Number of Products under Development for Diabetic Gastroparesis, H1 2015 8

Number of Products under Development for Diabetic Gastroparesis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Top 10 Targets, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Top 10 Molecule Types, H1 2015 29

Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Cempra, Inc.

Evoke Pharma, Inc.

GlaxoSmithKline plc

Ironwood Pharmaceuticals, Inc.

Rhythm Pharmaceuticals

Shire Plc

Targacept, Inc.

Diabetic Gastroparesis Therapeutic Products under Development, Key Players in Diabetic Gastroparesis Therapeutics, Diabetic Gastroparesis Pipeline Overview, Diabetic Gastroparesis Pipeline, Diabetic Gastroparesis Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com